Study Design and Progress

NCT03854318, sponsored by the National Human Genome Research Institute (NHGRI), is a prospective cohort natural history study tracking individuals with germline RUNX1 variants and their families. Initiated in 2019 and ongoing with renewal through March 2026, the study is conducted at the NIH Clinical Center in Maryland, USA, without age restrictions. As a non-interventional observational study, it is not classified under Phase 1, 2, or 3 trials. Annual clinical evaluations, genomic analyses, and specimen collections (blood, saliva, oral cells, and optional bone marrow) are performed. The core value lies in elucidating the temporal sequence of clonal hematopoiesis and malignant transformation, rather than focusing solely on platelet counts at a single time point.

Accumulated Clinical Evidence

A 2023 study published in Blood reported that 214 participants were enrolled between 2019 and 2021, including 111 patients and 45 unrelated family members with 39 distinct RUNX1 variants. In a separate European cohort, 44.8% (60 out of 134 evaluable participants) experienced hematologic malignancies, primarily acute myeloid leukemia (AML, 26.9%) and myelodysplastic syndrome (MDS, 13.4%). Recent literature estimates the lifetime risk of hematologic malignancy at 35–50%, suggesting that RUNX1-FPD should be viewed not merely as a bleeding disorder but as a hereditary predisposition syndrome to blood cancers. Detecting acquired mutations and clonal expansion in serial specimens could enable the development of biomarkers to determine transplant timing and design preventive clinical trials.

Treatment Landscape and Competitive Pipeline

Current management of bleeding includes desmopressin, tranexamic acid, and platelet transfusions. Upon transformation to MDS or AML, standard chemotherapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT) are the primary treatment approaches. For low-intensity AML therapy, Venclexta (venetoclax), which inhibits BCL-2, is used and was granted FDA accelerated approval on November 21, 2018, by AbbVie (ABBV) and Roche (ROG) subsidiary Genentech. A competitive development targeting RUNX1-FPD itself is NCT06261060, a Phase 2 trial at MD Anderson Cancer Center using Rapamune (sirolimus) to modulate mTORC1 signaling and hematopoietic function, aiming to enroll 6 participants. Although Rapamune was FDA approved on September 15, 1999, for kidney transplant rejection prevention, its use in RUNX1-FPD is in repurposing development.

Market and Industry Implications

As a rare genetic disorder, RUNX1-FPD lacks an independent commercial market, with economic value largely tied to AML treatment and transplant demand following malignant transformation. According to Fortune Business Insights, the global AML treatment market is projected to reach USD 3.91 billion in 2025 and USD 9.79 billion by 2034. Natural history data from small patient populations can inform clinical endpoints, risk stratification, and external control group design, thereby reducing trial failures in gene editing, preventive transplantation, and targeted therapy development. However, the study itself does not validate therapeutic efficacy, so investment value realization depends on whether predictive biomarkers are prospectively validated and linked to interventional trials.